Subscribe to Pro or Enterprise plans to unlock this feature.
Become a smarter investor today.
Become a smarter investor today.
This statistic highlights Becton Dickinson’s revenue by segment, split across Medical, Life Sciences and Interventional segments.
|Segment||Q4 2020||Q3 2021||Q4 2021||Contribution in Q4 2021|
(All the values are in billions, except for percentages)
The sum of revenue by all segments in Q4 2021 is $5.14 billion, marking a rise in year-on-year (YoY) and quarter-on-quarter (QoQ) revenue when compared to Q4 2020 and Q3 2021, respectively. On the YoY scale, the growth is $0.36 billion which indicates a 7.36% incline. On the QoQ scale, the overall growth rate is 5.01% of $4.89 billion. The total revenue medical segment has the highest contributor of 49.31% and the lowest contribution is from the interventional segment of 20.86% of the revenue generated in Q4 2021.
The medical segment revenue sources are – Medication Delivery Solutions, Pharmaceutical Systems, Diabetes Care units, and other Medication Management Solution units. It has earned a revenue of $2.53 billion in Q4 2021, making it the largest earning segment amongst the three segments by contributing 49.31% of the total revenue earned by the company in Q4 2021. Under the YoY scale, the company has earned 9.28% more than when compared to the revenue of Q4 2020 at $2.32 billion. Under QoQ, the company’s revenue increased by 6.61% when compared to the revenue earned of $2.38 billion in Q3 2021.
The manufacturing overhead cost in 2020 was recorded at $224 million as compared to $56 million in 2021, for predicted future cost within the Medication Management Solutions unit associated with redressing efforts related to Alaris infusion pumps.
This segment in 2020 was driven by the Integrated Diagnostic Solution unit’s sales, especially in Q4 which related to COVID-19 diagnostic testing kits. A positive impact on the product mix from the Integrated Diagnostic unit and the recovery of demand for other products with higher margins. In 2021, the manufacturing overhead cost was recognized in the duration because of the COVID. The COVID-19 testing inventory was in excess that was worth $93 million was recognized in 2021 that became obsolete and adversely affected the net revenue of 2021.
The Life Sciences segment includes Integrated Diagnostic Solution – blood collection and sampling systems, molecular testing systems, HPV tests for cervical cancer, etc. It has generated a revenue of $1.53 billion in Q4 2021 which contributed 29.83% of the total revenue generated. The segment depicted an incline in QoQ and YoY. On the QoQ scale, the company has given 6.91% higher revenue when compared to Q3 2021 at $1.43 billion resulting in an absolute $0.1 billion. On the YoY index, the company has inclined its revenue by 2.96% when compared to the revenue of Q4 2020 at $1.49 billion.
The revenue of the interventional segment is higher in 2021 compared with 2020 because of the recovery of demand for products with high margins. The revenue in the prior-year period was unfavorable because the manufacturing overhead costs increased due to the pandemic. Selling and administrative cost as a percentage of revenue in 2021 was also low when compared to the selling and administrative cost of 2020 because of the demand recovery in 2021. The expiry of the contract of royalty income steam with Bard was also reflected in lower revenue in 2020.
Interventional revenue sources are from sales of Surgical products, Peripheral Intervention, and Urology and Critical Care. Revenue generated in Q4 2021 is $1.07 billion showing a decrease of 1.02% in QoQ when compared to the revenue of Q3 2021 at $1.08 billion but in the YoY, the revenue has upscaled by 9.51% compared to Q4 2020 revenue of $0.98 billion. They also contributed the most to the revenue of the company in Q4 2021.
COVID resulted in a significant decline in medical procedures in the fiscal year 2020. In the 2021 fiscal year, the demand however showed substantial recovery, but the regional resurgence in COVID-19 infections and emergence of Delta Variant continued impacting the demand for certain B.D. products. COVID-19 diagnostic testing substantially benefitted the sales of 2021. The future operating performance, especially in short term is subject to volatility. B.D. had also been facing challenges posed by the pandemic to global transportation channels and other aspects of their supply chain, including cost and availability of raw material, as well the logistical problem of moving finished, semi-finished goods around the globe.
About the company
Becton, Dickinson, and Company is a global medical technology company that is engaged in the development, manufacturing, and sales of a broad range of medical devices, supplies, diagnostic products, and laboratory equipment used in healthcare institutions, physicians, clinical laboratories, the general public, and the pharmaceutical industry. Their products are marketed in the U.S and internationally directly to end-users and through independent distribution channels. The operation that is outside the states in – Latin America, Greater Asia, EMEA – that is Europe, The middle east, Africa; and Canada.
Did you like Sunworks’ Revenue by Segment statistic?
Access more such KPI data points and segment financials on thousands of US stocks, with Business Quant.
You can get started here.
Always know what you’ll pay. No hidden costs or surprises.
* Billed annually, local taxes extra.
* Local taxes extra.